AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10491062 — intervention group
Group type: COMPARATOR
Intervention: Standard dry dressing
Number of subjects: 10
Study 8580576 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-failure diet containing well-polished rice
Number of subjects: 3
Study 8580576 — intervention group
Group type: COMPARATOR
Intervention: Standard liver-failure diet containing conventionally processed rice
Number of subjects: 3
Study 2123914 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate (Is-5-Mn), 40 mg b.i.d. for 3 months
Number of subjects: 11
Study 2123914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7013895 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine (Disadine DP)
Number of subjects: 153
Study 7013895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 153
Study 7013895 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine (Disadine DP) on contaminated wounds
Number of subjects: 153
Study 7013895 — intervention group
Group type: COMPARATOR
Intervention: Control group (contaminated wounds)
Number of subjects: 153
Study 30738433 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen 480 mg/day for 48 weeks
Number of subjects: 40
Study 30738433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar dosages without zaltoprofen)
Number of subjects: 40
Study 31161196 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma copper (per SD increment)
Number of subjects: 1236
Study 31161196 — intervention group
Group type: COMPARATOR
Intervention: Plasma copper (quartile 4 ≥ 117.0 μg/dL)
Number of subjects: 1236
Study 31161196 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma copper
Number of subjects: 1236
Study 28601167 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention targeting attitude towards restrictive dietary behaviors
Number of subjects: 70
Study 28601167 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education (3 weekly 60-minute sessions)
Number of subjects: 70
Study 25440281 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification score (RSS) based on multivariable logistic regression model incorporating 18 covariates; assigned values based on odds ratios (ORs).
Number of subjects: 10963
Study 25440281 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model's predicted rates of renal failure.
Number of subjects: 10963
Study 23526069 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG) alone
Number of subjects: 31
Study 23526069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG) with omentectomy
Number of subjects: 31
Study 21777463 — intervention group
Group type: EXPERIMENTAL
Intervention: Training, feedback, and tailored interventions
Number of subjects: 22
Study 21777463 — intervention group
Group type: COMPARATOR
Intervention: Training and feedback
Number of subjects: 22
Study 18336986 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct technique (G1)
Number of subjects: 20
Study 18336986 — intervention group
Group type: COMPARATOR
Intervention: Indirect technique (G2)
Number of subjects: 20
Study 15983814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (SH) eyedrops
Number of subjects: 13
Study 15983814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate (SH) eyedrops
Number of subjects: 13
Study 15983814 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 13
Study 12627702 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% commercial chlorhexidine solution (Cav Clean) applied for 40 seconds after acid etching
Number of subjects: 30
Study 12627702 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid for 15 seconds (Group I)
Number of subjects: 30
Study 12627702 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel containing 2% digluconate of chlorhexidine (Cond AC) for 15 seconds (Group III)
Number of subjects: 30
Study 12627702 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 9093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care for anemia including erythropoietin and red blood cell transfusions
Number of subjects: 0
Study 9093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of myeloid growth factors G-CSF and GM-CSF for neutropenia
Number of subjects: 0
Study 9093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy for immune-mediated thrombocytopenia including zidovudine, corticosteroids, IVGG, and splenectomy
Number of subjects: 0
Study 9093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions for thrombocytopenia caused by decreased production
Number of subjects: 0
Study 9093237 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific therapy for asymptomatic hypergammaglobulinemia and lupus anticoagulants
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐14C]leucine
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [4,5‐3H]leucine
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐14C]alpha‐ketoisocaproate (KIC)
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [4,5‐3H]KIC
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]leucine
Number of subjects: 0
Study 8344335 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]KIC
Number of subjects: 0
Study 3579357 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b (1 X 10(6) U per site, intralesional)
Number of subjects: 11
Study 3579357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralesional)
Number of subjects: 11
Study 3579357 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b (5 X 10(6) U, intramuscular)
Number of subjects: 11
Study 29076028 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 (doses: 0.5, 1, 2, 5, 10, 25, 50, 100, 150 mg)
Number of subjects: 83
Study 29076028 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 (25 mg tablet)
Number of subjects: 83
Study 29076028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 26634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivational priming
Number of subjects: 42
Study 26634389 — intervention group
Group type: COMPARATOR
Intervention: Neutral motivational priming
Number of subjects: 42
Study 25226476 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1062
Study 25226476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 21925260 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of lipopolysaccharide (LPS)
Number of subjects: 20
Study 21925260 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 20
Study 20857862 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional visual scoring of sleep stages and EEG spectral analysis
Number of subjects: 90
Study 20857862 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG spectral analysis
Number of subjects: 90
Study 20857862 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional scoring and EEG spectral analysis
Number of subjects: 90
Study 20857862 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 90
Study 18078449 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin (5 mg)
Number of subjects: 51
Study 16759445 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clot removal
Number of subjects: 0
Study 16759445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of tissue plasminogen activator
Number of subjects: 0
Study 16759445 — intervention group
Group type: COMPARATOR
Intervention: Guglielmi detachable coils (GDC)
Number of subjects: 0
Study 16759445 — intervention group
Group type: COMPARATOR
Intervention: Clipping cases
Number of subjects: 0
Study 12846543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 60
Study 12846543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% isoflurane
Number of subjects: 60
Study 12846543 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia drugs
Number of subjects: 60
Study 11209536 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 IU recombinant FSH
Number of subjects: 15
Study 11209536 — intervention group
Group type: COMPARATOR
Intervention: 50 IU recombinant FSH
Number of subjects: 15
Study 8673559 — intervention group
Group type: COMPARATOR
Intervention: Class I (80.05% of the population sample)
Number of subjects: 2000
Study 8673559 — intervention group
Group type: EXPERIMENTAL
Intervention: Classes II, III, and IV (19.95% of the population)
Number of subjects: 2000
Study 8673559 — intervention group
Group type: EXPERIMENTAL
Intervention: Classes III and IV (10.85% of the population)
Number of subjects: 2000
Study 8673559 — intervention group
Group type: EXPERIMENTAL
Intervention: Classes III and IV
Number of subjects: 2000
Study 8673559 — intervention group
Group type: EXPERIMENTAL
Intervention: Classes II, III, and IV
Number of subjects: 2000
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic with usual diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic with weight loss diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic with low sodium/high potassium diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker with usual diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker with weight loss diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker with low sodium/high potassium diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: COMPARATOR
Intervention: Placebo with usual diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: COMPARATOR
Intervention: Placebo with weight loss diet
Number of subjects: 0
Study 2649308 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low sodium/high potassium diet
Number of subjects: 0
Study 329858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2-5 mg twice daily)
Number of subjects: 21
Study 329858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30923873 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (leg kicks for 1 hour) in young individuals
Number of subjects: 0
Study 30923873 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced activity (2 weeks immobilization of one leg) in young individuals
Number of subjects: 0
Study 30923873 — intervention group
Group type: EXPERIMENTAL
Intervention: Old tendons
Number of subjects: 0
Study 28873749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06mg/kg norbixin (NBIX)
Number of subjects: 12
Study 28873749 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2mg/kg bixin (BIX)
Number of subjects: 12
Study 28873749 — intervention group
Group type: COMPARATOR
Intervention: High-calorie meal without carotenoid (placebo)
Number of subjects: 12
Study 25936724 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses across three dose levels)
Number of subjects: 206
Study 25936724 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 (three doses at the highest dose level)
Number of subjects: 206
Study 25936724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 25936724 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses)
Number of subjects: 206
Study 23730991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (achieved BP ≤140/90 mm Hg)
Number of subjects: 724
Study 23730991 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment (achieved BP ≤150/90 mm Hg)
Number of subjects: 724
Study 21233810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 88
Study 21233810 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 88
Study 21233810 — intervention group
Group type: COMPARATOR
Intervention: No pioglitazone
Number of subjects: 88
Study 21233810 — intervention group
Group type: COMPARATOR
Intervention: No resistance training
Number of subjects: 88
Study 19672186 — intervention group
Group type: EXPERIMENTAL
Intervention: CR665 (0.36 mg/kg) administered intravenously over 1 h
Number of subjects: 0
Study 19672186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg) administered orally
Number of subjects: 0
Study 19672186 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously and orally
Number of subjects: 0
Study 22328063 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (Arco®) - single dose (125 mg artemisinin and 50 mg naphthoquine)
Number of subjects: 174
Study 22328063 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem®) - three-day regimen (20 mg artemether and 120 mg lumefantrine)
Number of subjects: 174
Study 22328063 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (Arco®)
Number of subjects: 174
Study 22328063 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem®)
Number of subjects: 174
Study 22328063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study 15516356 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 15516356 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 9658725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 220
Study 9658725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by transplantation (allogeneic or autologous)
Number of subjects: 220
Study 9658725 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 220
Study 8128082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antegrade‐retrograde cardioplegia with perfusion into the right atrium
Number of subjects: 40
Study 8128082 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegia through the aortic root
Number of subjects: 40
Study 2577483 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated 5-ASA (Claversal) 0.75 g/day
Number of subjects: 334
Study 2577483 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine 1.5-2.0 g/day
Number of subjects: 334
Study 2577483 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated 5-ASA
Number of subjects: 334
Study 2577483 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 334
Study 329621 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene (TCE) exposure
Number of subjects: 7
Study 329621 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 7
Study 31910674 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback interaction guidance intervention (3 sessions during home visits at 3-week intervals)
Number of subjects: 12
Study 31910674 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 home visits on the same schedule as intervention)
Number of subjects: 12
Study 31910674 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback interaction guidance intervention
Number of subjects: 12
Study 31910674 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 29769505 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg 0.5% hyperbaric bupivacaine
Number of subjects: 72
Study 29769505 — intervention group
Group type: EXPERIMENTAL
Intervention: 15mg 0.5% hyperbaric bupivacaine plus 5mg dexamethasone
Number of subjects: 72
Study 27383931 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic lobectomy
Number of subjects: 10
Study 23524886 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 1684
Study 23524886 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 1684
Study 23524886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study 23524886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both belimumab doses
Number of subjects: 1684
Study 23298524 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental omega-3 fatty acids (3.18 g daily of eicosapentaenoic acid and 822 mg daily of docosahexaenoic acid)
Number of subjects: 0
Study 23298524 — intervention group
Group type: COMPARATOR
Intervention: Matched control soy oil
Number of subjects: 0
Study 23298524 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental omega-3 fatty acids
Number of subjects: 0
Study 20859868 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg daily for 1 month
Number of subjects: 38
Study 20859868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18445899 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL + 40 mg of furosemide
Number of subjects: 87
Study 18445899 — intervention group
Group type: COMPARATOR
Intervention: Standard ESWL
Number of subjects: 87
Study 15986358 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention
Number of subjects: 142
Study 12558462 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 or 100 mg/day
Number of subjects: 1513
Study 12558462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 10338106 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g piracetam daily for 4 weeks and maintenance treatment for 8 weeks
Number of subjects: 927
Study 10338106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 10338106 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g piracetam
Number of subjects: 927
Study 7860900 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 278
Study 7860900 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 278
Study 7860900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of APSAC and rt-PA
Number of subjects: 278
Study 1781340 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (administered prenatally in a small dose)
Number of subjects: 0
Study 1781340 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (in utero exposure)
Number of subjects: 0
Study 1781340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to xenobiotics
Number of subjects: 0
Study 7282057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loperamide, doses of 2-6 mg per day
Number of subjects: 7
Study 31148398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production (EHFP)
Number of subjects: 900
Study 31148398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production plus fishponds (EHFP + F)
Number of subjects: 900
Study 31148398 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 900
Study 28228428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure treatment (target <120/80 mm Hg)
Number of subjects: 184
Study 28228428 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment (target <140/90 mm Hg)
Number of subjects: 184
Study 28228428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure treatment
Number of subjects: 184
Study 28228428 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 184
Study 25795641 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Bolus Advisors (BAs)
Number of subjects: 0
Study 25795641 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24096552 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (8 mg/day as copper sulfate)
Number of subjects: 60
Study 24096552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22093394 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowe Critical Appraisal Tool (CCAT group)
Number of subjects: 10
Study 22093394 — intervention group
Group type: COMPARATOR
Intervention: Informal appraisal (IA group)
Number of subjects: 10
Study 19477399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring using OptiVol in Medtronic implantable devices
Number of subjects: 500
Study 19477399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal 'alarm' threshold value for identification of episodes of decompensation
Number of subjects: 500
Study 19477399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Trend data after a true positive alarm
Number of subjects: 500
Study 18180892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaozhi Yanggan Decoction (TZYGD)
Number of subjects: 101
Study 18180892 — intervention group
Group type: COMPARATOR
Intervention: Thiola (Control)
Number of subjects: 101
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic heparin with Hemophan membrane
Number of subjects: 10
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with Hemophan membrane
Number of subjects: 10
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic heparin with ethylene vinyl alcohol membrane
Number of subjects: 10
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with ethylene vinyl alcohol membrane
Number of subjects: 10
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic heparin with polyacrylonitrile membrane
Number of subjects: 10
Study 15345918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin with polyacrylonitrile membrane
Number of subjects: 10
Study 10858407 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 32
Study 10858407 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 32
Study 9105569 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 g three times per day for 3 days)
Number of subjects: 10